Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.56 |
| ▸ | HTR3B | O95264 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29656856 | 0.84 | HTR3E (0.73) | L3MBTL1AKR1C3HTR3EHTR3BADRB1 | |
| SCHEMBL28599511 | 0.84 | HTR3E (0.73) | L3MBTL1AKR1C3HTR3EHTR3BADRB1 | |
| SCHEMBL11435336 | 0.84 | HTR3E (0.58) | L3MBTL1AKR1C3HTR3EHTR3BADRB1 | |
| SCHEMBL20456231 | 0.83 | L3MBTL1 (0.51) | L3MBTL1AKR1C3HTR3EHTR3BADRB1 | |
| SCHEMBL28323351 | 0.81 | MAPT (0.55) | L3MBTL1LMNATSHRSMN1; SMN2MAPT | |
| SCHEMBL2359935 | 0.81 | ADRB1 (0.59) | ADRB1SMN1; SMN2MAPTKMT2ADRD2 | |
| SCHEMBL29786218 | 0.81 | ADRB1 (0.59) | ADRB1SMN1; SMN2MAPTKMT2ADRD2 | |
| SCHEMBL6153220 | 0.81 | ALDH1A1 (0.66) | L3MBTL1HTR3EHTR3BADRB1HTR3A | |
| SCHEMBL28522648 | 0.81 | LTA4H (0.60) | LMNATSHRSMN1; SMN2MAPTKMT2A | |
| SCHEMBL22892260 | 0.80 | FFAR4 (0.46) | ADRB1LMNATSHRSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110337293-A | Therapeutic compound | 新泽西鲁特格斯州立大学 | 2019-10-15 | — | — | CN | claimed |
| US-8288424-B2 | Substituted tetrahydroimidazopyridine compounds and the use thereof in the treatment of pain and other conditions | GRUENENTHAL GMBH (DE) | 2012-10-16 | — | — | US | claimed |
| CN-115551850-A | Small molecule inhibitors of galectin-3 | 百时美施贵宝公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-111377846-B | Piperazine benzamide derivative and application thereof | 江苏恩华药业股份有限公司 | 2022-05-24 | — | — | CN | disclosed |
| CN-111377846-A | Piperazine benzamide derivative and application thereof | 江苏恩华药业股份有限公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-110337293-A | Therapeutic compound | 新泽西鲁特格斯州立大学 | 2019-10-15 | — | — | CN | disclosed |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| CN-103983627-A | Pyridopyrimidine compounds as anti-tubercular agents | PASTEUR INSTITUT KOREA | 2014-08-13 | — | — | CN | disclosed |
| EP-2146990-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-01-27 | — | — | EP | disclosed |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| WO-2008145839-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | OGFRL1, OPRL1, ORMDL3 | L3MBTL1 515/4885AKR1C3 568/4885HTR3E 211/4885 |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | MAP3K19, MAP3K2, MAP3K3 | L3MBTL1 747/4885AKR1C3 1163/4885HTR3E 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.